BR112018016774A2 - veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio - Google Patents
veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônioInfo
- Publication number
- BR112018016774A2 BR112018016774A2 BR112018016774-6A BR112018016774A BR112018016774A2 BR 112018016774 A2 BR112018016774 A2 BR 112018016774A2 BR 112018016774 A BR112018016774 A BR 112018016774A BR 112018016774 A2 BR112018016774 A2 BR 112018016774A2
- Authority
- BR
- Brazil
- Prior art keywords
- acromegaly
- tumors
- diabetes
- cancer
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 6
- 206010000599 Acromegaly Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title abstract 2
- 239000005556 hormone Substances 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- ABFNTRQPWNXUHA-VEVJRHMJSA-N C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(CC(N)=O)CCCC(=O)NCCCC(=O)N1)=O)[C@H](O)C)C1=CC=CC=C1 Chemical compound C([C@H]1C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CC=2C=CC=CC=2)C(=O)N(CC(N)=O)CCCC(=O)NCCCC(=O)N1)=O)[C@H](O)C)C1=CC=CC=C1 ABFNTRQPWNXUHA-VEVJRHMJSA-N 0.000 title 1
- 201000001421 hyperglycemia Diseases 0.000 title 1
- 230000004962 physiological condition Effects 0.000 title 1
- 229950007162 veldoreotide Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 206010022095 Injection Site reaction Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 239000000644 isotonic solution Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção proporciona composições compreendendo peptídeos solúveis em água com fraca solubilidade em soluções isotônicas que exibem biodisponibilidade aumentada com efeitos adversos reduzidos, incluindo reações no local de injeção. são também descritos métodos para uso de tais composições para o tratamento de doenças incluindo, mas não limitadas ao câncer, diabetes tipo 2, acromegalia, distúrbios metabólicos, distúrbios endócrinos, tumores exócrinos e tumores relacionados a hormônios. métodos para reduzir as reações adversas no local de injeção e melhorar a biodisponibilidade também são divulgados.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662295545P | 2016-02-16 | 2016-02-16 | |
| US62/295,545 | 2016-02-16 | ||
| PCT/IB2017/000194 WO2017141106A1 (en) | 2016-02-16 | 2017-02-16 | Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia, and hormone-related tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018016774A2 true BR112018016774A2 (pt) | 2018-12-26 |
Family
ID=58448573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018016774-6A BR112018016774A2 (pt) | 2016-02-16 | 2017-02-16 | veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP3416666B1 (pt) |
| JP (1) | JP7030720B2 (pt) |
| CN (1) | CN109462982A (pt) |
| AU (1) | AU2017220728A1 (pt) |
| BR (1) | BR112018016774A2 (pt) |
| CA (1) | CA3014406A1 (pt) |
| ES (1) | ES2906791T3 (pt) |
| RU (1) | RU2736590C2 (pt) |
| WO (1) | WO2017141106A1 (pt) |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US6051554A (en) * | 1995-06-07 | 2000-04-18 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| US6355613B1 (en) * | 1996-07-31 | 2002-03-12 | Peptor Limited | Conformationally constrained backbone cyclized somatostatin analogs |
| EP0880969A1 (en) | 1997-05-28 | 1998-12-02 | Applied Research Systems ARS Holdings N.V. | Pharmaceutical compositions of peptides having low solubility in physiological medium |
| WO2004069187A2 (en) | 2003-02-03 | 2004-08-19 | Shire Laboratories, Inc. | Drug formulation and delivery using crystalline methylated cyclodextrins |
| NZ556627A (en) * | 2005-02-22 | 2010-09-30 | Pfizer | Oxyindole derivatives as 5HT4 receptor agonists |
| EP2350118B1 (en) * | 2008-09-19 | 2016-03-30 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| US20100086597A1 (en) * | 2008-10-06 | 2010-04-08 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide with a low initial burst |
| AU2010280688A1 (en) * | 2009-08-05 | 2012-02-23 | Allergan, Inc. | Controlled release formulations of lipocalin muteins |
| WO2011087496A1 (en) * | 2010-01-13 | 2011-07-21 | Oakwood Laboratories LLC | Microspheres for the sustained release of octreotide without an initial time lag |
| CN111249255A (zh) * | 2020-03-04 | 2020-06-09 | 烟台大学 | 温敏水凝胶载药的新型微球复合制剂及制备方法 |
-
2017
- 2017-02-16 JP JP2018561098A patent/JP7030720B2/ja active Active
- 2017-02-16 WO PCT/IB2017/000194 patent/WO2017141106A1/en active Application Filing
- 2017-02-16 AU AU2017220728A patent/AU2017220728A1/en not_active Abandoned
- 2017-02-16 ES ES17714266T patent/ES2906791T3/es active Active
- 2017-02-16 CA CA3014406A patent/CA3014406A1/en active Pending
- 2017-02-16 CN CN201780023841.6A patent/CN109462982A/zh active Pending
- 2017-02-16 BR BR112018016774-6A patent/BR112018016774A2/pt not_active IP Right Cessation
- 2017-02-16 EP EP17714266.8A patent/EP3416666B1/en active Active
- 2017-02-16 RU RU2018132631A patent/RU2736590C2/ru active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019504897A (ja) | 2019-02-21 |
| EP3416666A1 (en) | 2018-12-26 |
| AU2017220728A1 (en) | 2018-08-23 |
| EP3416666B1 (en) | 2021-10-27 |
| RU2018132631A3 (pt) | 2020-05-13 |
| RU2736590C2 (ru) | 2020-11-18 |
| CA3014406A1 (en) | 2017-08-24 |
| WO2017141106A1 (en) | 2017-08-24 |
| ES2906791T3 (es) | 2022-04-20 |
| CN109462982A (zh) | 2019-03-12 |
| RU2018132631A (ru) | 2020-03-17 |
| JP7030720B2 (ja) | 2022-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017003185A1 (es) | Compuestos co-agonistas del glucagón y péptido-1 similar al glugacón (glp-1) | |
| BR112017008160A8 (pt) | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição | |
| CU20190056A7 (es) | Ácidos carboxílicos de benzimidazoles y 4-aza, 5-aza, 7-aza y 4,7-diaza-benzimidazoles como agonistas receptores de glp-1, útiles para tratar o prevenir enfermedades cardiometabólicas | |
| CY1120583T1 (el) | Σκευασματα ινσουλινης για γρηγορη προσληψη | |
| BR112018073511A2 (pt) | polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos | |
| NI201700032A (es) | Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del higado graso no alcohólico | |
| MX2022006107A (es) | Metodos y composiciones para dosificacion en terapia celular adoptiva. | |
| BR112019000528A2 (pt) | distribuição mediada por ve de conjugados de proteína de ligação-molécula pequena | |
| BR112018003017A2 (pt) | anticorpos anti-bcma, moléculas biespecíficas de ligação ao antígeno que liga bcma e cd3, e usos dos mesmos | |
| NI201500093A (es) | Modulador del receptor de andrógenos y usos de este | |
| BR112016020953A2 (pt) | composto, kit, composição farmacêutica, uso de composto, método de tratamento e invenção | |
| MX2014003579A (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor de glucocorticoide. | |
| CL2015003199A1 (es) | Peptidos terapeuticos | |
| MX356295B (es) | Análogos de péptido de la hormona de estimulación de alfa-melanocito. | |
| DOP2016000102A (es) | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y su uso | |
| EA201390194A1 (ru) | Улучшенный рекомбинантный фолликул-стимулирующий гормон человека | |
| WO2014151369A3 (en) | Stabilized ezh2 peptides | |
| MX2019003567A (es) | Peptidos terapeuticos relacionados con mots-c. | |
| BR112017009552A2 (pt) | métodos para alvejar o controle transcricional em regiões de super-realçador | |
| EA201591581A1 (ru) | Способы лечения псориаза при помощи анти-il-23 антитела | |
| CO2017005201A2 (es) | Ácido benzóico, derivados de ácido benzóico y conjugados heteroarilcarboxílico de la oxicodona | |
| PH12015502556A1 (en) | Modified release formulation | |
| MX2022012075A (es) | Formulaciones de farmacos de moleculas peque?as resistentes a precipitacion. | |
| MY186134A (en) | Curcumin-peptide conjugates and formulations thereof | |
| BR112018016774A2 (pt) | veldoreotídeo com fraca solubilidade em condições fisiológicas para o uso no tratamento da acromegalia, câncer em acromegalia, tumores que expressam sst-r5, diabetes tipo 2, hiperglicemia e tumores relacionados a hormônio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: STRONGBRIDGE DUBLIN LIMITED (US) |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |